Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

PHASE3CompletedINTERVENTIONAL
Enrollment

552

Participants

Timeline

Start Date

March 13, 2017

Primary Completion Date

August 17, 2017

Study Completion Date

August 17, 2017

Conditions
Chronic Idiopathic Constipation
Interventions
DRUG

Lubiprostone

24 mcg administered orally BID

DRUG

Placebo

24 mcg administered orally BID

Trial Locations (67)

10459

Investigative Site, The Bronx

19152

Investigative Site, Philadelphia

20815

Investigative Site, Chevy Chase

21742

Investigative Site, Hagerstown

23220

Investigative Site, Richmond

23606

Investigative Site, Newport News

27262

Investigative Sitee, High Point

27612

Investigative Site, Raleigh

29303

Investigative Site, Spartanburg

29406

Investigative Site, Charleston

30078

Investigative Site, Snellville

30281

Investigative Site, Stockbridge

30607

Investigative Site, Athens

32129

Investigative Sitee, Port Orange

32720

Investigative Site, DeLand

32806

Investigative Site, Orlando

33012

Investigative Site, Hialeah

33065

Investigative Site, Coral Springs

33142

Investigative Site, Miami

33143

Investigative Site 2, Miami

Investigative Site, Miami

33165

Investigative Site, Miami

33322

Investigative Site, Plantation

33409

Investigative Site, West Palm Beach

33458

Investigative Site, Jupiter

33609

Investigative Site, Tampa

33634

Investigative Site, Tampa

33765

Investigative Site, Clearwater

34952

Investigative Site, Port Saint Lucie

35216

Investigative Site, Birmingham

36535

Investigative Site, Foley

37421

Investigative Site, Chattanooga

38305

Investigative Site 2, Jackson

Investigative Site, Jackson

39202

Investigative Site, Jackson

44060

Investigative Site, Mentor

44122

Investigative Site, Cleveland

68005

Investigative Sitee, Bellevue

70124

Investigative Site, New Orleans

70601

Investigative Site, Lake Charles

71101

Investigative Site, Shreveport

72212

Investigative Site, Little Rock

73110

Investigative Site, Midwest City

75605

Investigative Site, Longview

77058

Investigative Site, Houston

77099

Investigative Site, Houston

77479

Investigative Site, Sugar Land

78504

Investigative Site, McAllen

80909

Investigative Site, Colorado Springs

83221

Investigative Site, Blackfoot

83642

Investigative Site, Meridian

83712

Investigative Site, Boise

84041

Investigative Site, Layton

84088

Investigative Site, West Jordan

84123

Investigative Site, Taylorsville

89119

Investigative Site, Las Vegas

90057

Investigative Site, Los Angeles

90806

Investigative Site, Long Beach

91402

Investigative Site, Panorama City

91786

Investigative Site, Upland

91910

Investigative Sitee, Chula Vista

92078

Investigative Site, San Marcos

92103

Investigative Site, San Diego

92805

Investigative Site, Anaheim

92840

Investigative Site, Garden Grove

06320

Investigative Site, New London

02740

Investigative Site, New Bedford

All Listed Sponsors
collaborator

Sucampo AG

INDUSTRY

collaborator

Sucampo Pharmaceuticals, Inc.

INDUSTRY

lead

Sucampo Pharma Americas, LLC

INDUSTRY

NCT03097861 - Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo | Biotech Hunter | Biotech Hunter